DocWire News Editors

DocwireNews

R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) plus lenalidomide improved response rates and survival in patients with transformed, untreated diffuse large B-cell lymphoma (DLBCL), according a study presented at the 2020 ASH Annual Meeting.&ldquo;Transformation of low-grade follicular lymphoma (FL) to DLBCL carries a poor prognosis. In retrospective studies, five-year survival of transformed DLBCL treated with R-CHOP without autologous hematopoietic cell transplant is 40% to 60%, underscoring need to improve frontline treatment of transformed DLBCL beyond R-CHOP,&rdquo; the authors wrote.The phase II clinical trial included adult patients with transformed DLBCL and either historical or concurrent FL; stage &ge;2, measurable disease by positron emission tomography/computed tomography; and adequate organ function. Patients with central nervous system involvement, significant comorbidities, active non-lymphomatous malignancy, life-threatening thromboembolism, and contraindication to aspirin prophylaxis were excluded.Evaluable patients (n=33; median age, 64 years; range, 24-80 years) received up to six cycles of rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, and vincristine 1.4 mg /m2 on day 1; prednisone 100 mg on days one through five; pegfilgrastim on day two; and lenalidomide 25 mg on days one through 10 of 21-day cycles.About half of patients (n=18; 54%) were &gt;60 years old. Eighteen patients (54%) were male, and 32 (97%) had Eastern Cooperative Oncology Group performance status score &lt;2. Twenty-three patients (70%) had historical FL, while 10 (30%) had concurrent FL. Twenty-six patients (79%) had advanced stage disease (III/IV).Median number of extranodal sites were one (range, 0-4 sites). Thirteen patients (39%) had high International Prognostic Index scores (4-5). Almost all patients (n=32; 97%) completed at least two treatment cycles, and 30 patients completed all cycles.The overall response rate was 97% (n=32), including 29 (88%) complete responses and three partial responses. Twelve-month event-free survival (primary endpoint) was 87.9% (95% confidence interval [CI], 71.8-96.6). Two-year progression-free and overall survival were 84.5% (95% CI, 72.8-98.0) and 96.9% (95% CI, 91-100), respectively.Four patients discontinued protocol early due to disease progression (n=1), adverse event (AE; n=1), refusal (n=1), and non-compliance (n=1). Thirty patients (91%) experienced grade &ge;3 hematologic AEs, including neutropenia (n=27; 82%), thrombocytopenia (n=16; 48%), and anemia (n=7; 21%). About half of patients (n=16; 48%) had grade &ge;3 non-hematologic AEs, including eight (24%) with febrile neutropenia. Three deaths occurred due to progressive DLBCL (n=1), acute myeloid leukemia (n=1), and malignant melanoma (n=1).&ldquo;This study supports the inclusion of anthracycline-na&iuml;ve patients with transformed DLBCL in future randomized studies of lenalidomide or other novel immunomodulatory analogues,&rdquo; the researchers concluded.ReferenceDesai SH, Laplant B, Macon WR, et al. Lenalidomide/RCHOP (R2CHOP) Produces High Response Rates and Overall Survival in New, Untreated Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma- Results from MC078E. Abstract 1192. Presented at the 62nd American Society of Hematology Annual Meeting &amp; Exposition, December 2-11, 2020.

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

HER2 Breast Cancer

Trodelvy Plus Keytruda Significantly Improves Progression-Free Survival in PD-L1+ mTNBC, Phase III Data Show

Triple-Negative Breast Cancer

Jordana Jampel

Actress Michelle Trachtenberg's Premature Death From Diabetes Reveals Dangers of Chronic Complications

Diabetes

Latest News

R-CHOP Plus Lenalidomide Improves Responses in Patients with Untreated DLBCL

ASH Annual Meeting 2020

R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) plus lenalidomide improved response rates and survival in patients with transformed, untreated ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe